1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Incyte Enters A Data-Rich Year On Path To Portfolio Diversification

Myelofibrosis, Dermatology, Oncology Readouts Ahead

 
• By Mandy Jackson

Incyte’s Jakafi-dominated portfolio gained Opzelura as a second source of significant revenue in 2021. While further diversification has been limited, new and existing R&D assets may deliver upside in 2024.

Science Research as a Concept for Presentation
Incyte anticipates many trial readouts and other R&D milestones in 2024 • Source: Shutterstock

Incyte Corporation’s oral JAK1/2 inhibitor Jakafi (ruxolitinib) has grown to dominate the myelofibrosis market since its approval in 2011. For many years, it was the company’s only commercial asset, and it remains Incyte’s top seller by a wide margin, but it is facing loss of exclusivity (LOE) in 2028. However, while it is under pressure to diversify its revenue base through new products, the company expects to achieve milestones for multiple assets in 2024 that could reach the market ahead of the Jakafi LOE.

Key Takeaways

  • Incyte will have several clinical trials readouts and other milestones in 2024 as the company seeks to diversify beyond Jakafi ahead of the drug’s loss of exclusivity in 2028.

Wilmington, DE-based Incyte’s pipeline is fueled by in-house research and development as well as business development activity, a strategy important...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

More from Therapy Areas

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.